v3.26.1
ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended 36 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Dec. 31, 2026
Keytruda royalties | Forecast        
Licensing Arrangements [Line Items]        
Percentage of net sales payable to alliance partner       2.50%
Keytruda royalties | Forecast | Bristol-Myers Squibb        
Licensing Arrangements [Line Items]        
Payment and royalty allocation       75.00%
Keytruda royalties | Forecast | Ono        
Licensing Arrangements [Line Items]        
Payment and royalty allocation       25.00%
Reblozyl License | Merck        
Licensing Arrangements [Line Items]        
Royalty expense $ 124 $ 106    
Reblozyl License | Merck | Minimum        
Licensing Arrangements [Line Items]        
Percentage of net sales payable to alliance partner 20.00%      
Reblozyl License | Merck | Maximum        
Licensing Arrangements [Line Items]        
Percentage of net sales payable to alliance partner 24.00%      
Winrevair* License | Merck        
Licensing Arrangements [Line Items]        
Percentage of net sales payable to alliance partner 22.00%      
Proceeds from royalties received $ 124 $ 42    
Diabetes business - royalties        
Licensing Arrangements [Line Items]        
Percentage of net sales payable to alliance partner     14.00%